Noxxon Pharma Licenses and Assigns Preclinical Spiegelmer® Programs to Aptarion
NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today…
NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today…
NOXXON Pharma stellte auf der 55. Jahrestagung der American Society of Hematology (ASH) in New Orleans vom 7.-10. Dezemb…
NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called…
NOXXON Pharma AG, ein biopharmazeutisches Unternehmen und Pionier bei der Entwicklung der eigenen, patentierten neuen Wi…
NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called…
NOXXON Pharma AG, ein biopharmazeutisches Unternehmen und Pionier bei der Entwicklung der eigenen, patentierten neuen Wi…
NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called…
Noxxon Pharma AG (website), announced today the appointment of Dr.Matthias Baumann as Chief Medical Officer and member o…
NOXXON Pharma AG (website) announced today that in addition to the financing of €33m which was recently announced on 27…
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chem…